Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10899797-B2
Publication Date
2021-01-26
Expiration Date
Abstract
We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
Core Innovation
The disclosure describes Serpin-derived peptides, including SP16, as anti-inflammatory and immune-modulating agents. It provides a method of decreasing serum TNF-α levels in a human subject by administering a composition containing a peptide that follows a specified amino-acid pattern and is 21 or fewer amino acids in length. The disclosure also reports peptide activity in preclinical models and TLR2 activation in cell assays.
Preclinical findings associate the peptides with reduced inflammatory markers, lower TNF-α in an endotoxemia model, and suppressed inflammatory cytokine or MMP1 secretion. Additional reported outcomes include reduced paw swelling in arthritis models, improved glycemic measures, and delayed diabetes onset. The disclosure identifies oral administration and peptide variants without an explicit background description of the underlying problem.
Claims Coverage
The claims identify one independent claim that contains one inventive feature directed to decreasing serum TNF-α levels in a human subject using a peptide composition.
Decreasing serum TNF-α levels using a peptide composition
Administering to a human subject a composition comprising a peptide defined by a specified variable amino-acid sequence pattern and having a length of 21 or fewer amino acids to decrease serum TNF-α levels.
The independent claim centers on administering the defined peptide composition of 21 or fewer amino acids to decrease serum TNF-α levels in a human subject.
Stated Advantages
Decreases serum TNF-α levels in a human subject, including reductions of at least 50% compared with levels prior to administration.
Reduces inflammatory markers and suppresses inflammatory cytokine or MMP1 secretion in cell assays.
Reduces paw swelling in a mouse arthritis model.
Improves glycemic measures in db/db mice and delays diabetes incidence in NOD mice.
Documented Applications
Decreasing serum TNF-α levels in a human subject.
Treatment of sepsis and endotoxemia in a human subject.
Treatment of arthritis, including collagen antibody-induced arthritis.
Treatment of type I and type II diabetes.
Oral administration of peptide variants.
Interested in licensing this patent?